Skip to main content
News Archive

AstraZeneca to buy ZS Pharma for $2.7 billion – Philadelphia Business Journal

By November 6, 2015May 22nd, 2025No Comments

astrazeneca-logo

AstraZeneca entered into a definitive agreement Friday to buy ZS Pharma, a California biotechnology company, for $2.7 billion.

ZS Pharma (NASDAQ: ZSPH) of San Mateo, Calif., has an application seeking approval for ZS-9, its experimental treatment for hyperkalaemia, under review with the Food and Drug Administration. A European marketing application is expected before the end of the year.

{iframe}http://www.bizjournals.com/philadelphia/morning_roundup/2015/11/astrazeneca-buy-zs-pharma-california-27-billion.html?ana=e_phil_bn_breakingnews&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1446841309{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.